Published in J Pharm Health Care Sci on March 08, 2016
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med (1977) 1.54
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc (2010) 1.15
Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis. Acta Oncol (1998) 1.01
Therapeutic drug monitoring in cancer management. Clin Chem (1993) 0.99
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol (2003) 0.93
Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials (1978) 0.86
Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther (2008) 0.86